Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/J&J report positive Xarelto results in Japanese AF patients

This article was originally published in Scrip

Executive Summary

Bayer and Johnson & Johnson have revealed data that formed part of its Japanese submission package for the oral daily anticoagulant Xarelto (rivaroxaban) for the prevention of stroke in patients with atrial fibrillation. The results, which were presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis in Kyoto, Japan, showed that the product met the primary endpoint in a Japanese Phase III atrial fibrillation study, by demonstrating non-inferior safety compared with warfarin.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts